Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Age affects efficacy of immunotherapy treatment for breast cancer, preclinical study revealson September 8, 2019 at 1:27 am
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications ...
- Improving cancer immunotherapy through nanotechnologyon September 6, 2019 at 3:30 am
The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient’s coordinated and adaptive immune system to fight ...
- Does Allergy Immunotherapy Work?on September 5, 2019 at 9:41 pm
Allergy immunotherapy or immune therapy (AIT) is used to treat many allergic conditions. About 50 million people experience allergies every year in the US alone, of which about 3 million are treated ...
- Sublingual Immunotherapy Safe, Effective For Peanut Allergyon September 5, 2019 at 12:38 pm
Peanut sublingual immunotherapy (SLIT) given in extended therapy up to 5 years provides significant desensitization for most peanut-allergic children, and is easy to use and safe, say the authors of a ...
- Immunotherapy: The Future of Cancer Treatmenton September 5, 2019 at 3:00 am
As an oncologist, nothing makes me happier than to find a therapy that works for one of my patients – something that halts that patient's cancer in its tracks. So I am particularly excited by recent ...
- Immunotherapy for Colon Canceron September 4, 2019 at 5:00 pm
This year it’s estimated that more than 100,000 new cases of colon cancer and an estimated 44,180 new cases of rectal cancer will be diagnosed in the U.S., according to the American Cancer Society.
- Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinationson September 3, 2019 at 7:26 am
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and ...
- Added Immunotherapy Post-Ablative Therapy for Metastatic Lung Canceron August 31, 2019 at 3:21 am
There is no standard approach to treatment for patients with oligometastatic non-small cell lung cancer (NSCLC); however, recent studies have shown a survival benefit in combining ablative therapy ...
- Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanomaon August 30, 2019 at 10:32 am
At the recent ASCO annual meeting in Chicago, Janice Mehnert, MD, of Rutgers Cancer Institute of New Jersey, spoke with MedPage Today about immune checkpoint and BRAF/MEK therapy for patients, and the ...
- Delivering immunotherapy directly to brain tumorson August 29, 2019 at 10:48 am
A new study gives insight into how immunotherapies, treatments that help the body's immune system fight cancer, might one day be delivered directly to the brain in order to treat brain tumors.
via Bing News